OncoMyx closes $50M Series B to advance cancer-killing payload platform
Phoenix-based OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B Capital Group with participation from LYZZ…
